SCHEMBL6199902

SCHEMBL6199902

O=C(OCc1ccccc1)N1CC[N]CCN(C(=O)OCc2ccccc2)CCOCC1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.82
MEN1 O00255 1/20 0.82
NPSR1 Q6W5P4 1/20 0.82
SMN1; SMN2 Q16637 4/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
CYP2C19 P33261 1/20 0.53
FKBP1A P62942 1/20 0.49
TP53 P04637 1/20 0.49
GRIN2B Q13224 4/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HTT P42858 1/20 0.46
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14095609 0.92 KMT2A (0.97) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL1337663 0.92 KMT2A (0.97) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL42127 0.92 MEN1 (0.66) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL6202694 0.90 MEN1 (0.64) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL31323430 0.86 KMT2A (0.86) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL5542597 0.86 MEN1 (0.59) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL15307911 0.83 MEN1 (0.81) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL22014628 0.83 MEN1 (0.80) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL27604377 0.82 MEN1 (0.78) KMT2AMEN1NPSR1SMN1; SMN2NPC1
SCHEMBL3970912 0.81 MEN1 (0.76) KMT2AMEN1NPSR1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1381392-A4 SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME TS CORP (KR) 2005-03-23 EP disclosed
EP-1381392-A1 SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME TS Corporation (KR) 2004-01-21 EP disclosed
US-20020165365-A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same ARTZYME BIOTECH CORPORATION (KR) 2002-11-07 US disclosed
WO-2002085413-A1 SYNTHETIC CATALYST FOR SELECTIVE CLEAVAGE OF PROTEIN AND METHOD FOR SELECTIVE CLEAVAGE OF PROTEIN USING THE SAME TS CORPORATION (KR) 2002-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165365-A1 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same CPN1, RNPEP, ANPEP KMT2A 3366/4885MEN1 1581/4885NPSR1 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.